央企创投母基金，开始出手了

Core Insights - The establishment of the Guoxin Venture Capital Fund and the Chengtong Science and Technology Investment Fund reflects a strategic move to support the development of strategic emerging industries and to provide "patient capital" for long-term investments [6][9]. Group 1: Guoxin Venture Capital Fund - The Guoxin Venture Capital Fund is selecting sub-fund management institutions without a submission deadline, following a "mature one, invest one" principle [2]. - The sub-fund's duration will not exceed August 25, 2039, with at least 70% of investments focused on strategic emerging industries and future industries [2]. - Each sub-fund's total scale should be no less than 200 million, with the mother fund's contribution not exceeding 20% of the sub-fund's total scale [2]. - The management fee during the investment period is capped at 2% per year of the mother fund's contribution, with potential flexibility [2]. Group 2: Chengtong Science and Technology Investment Fund - The Chengtong Science and Technology Investment Fund aims to establish a total scale of 300 billion, with the first phase set at 100 billion, focusing on seed, startup, and growth-stage technology innovation companies [3][5]. - The fund will target investments in hard technology sectors, including new materials, advanced manufacturing, and next-generation information technology, utilizing a combination of equity investment and ecological incubation strategies [4][5]. - The fund's design spans 15 years, aligning with the long-term nature of technology innovation and the need for substantial support for core technology demands over the next 3 to 10 years [5][6]. Group 3: Patient Capital Concept - The concept of "patient capital" emphasizes the need for long-term, stable investment that can withstand market cycles and tolerate risks associated with technology innovation [6][8]. - Recent policies encourage central enterprises to become more involved in venture capital, promoting a culture of strategic and value-based investments [8][9]. - The development of patient capital is seen as essential for fostering innovation and supporting early-stage investments in technology, which often carry higher risks and longer return timelines [8][9].